Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/32934
Type
ArticleCopyright
Open access
Embargo date
2019-11-03
Collections
- INI - Artigos de Periódicos [3650]
Metadata
Show full item record
EVALUATION OF THE DETERMINE RAPID SYPHILIS TP ASSAY USING SERA
Affilliation
National Center for HIV, STD, TB Prevention. Centers for Disease Control and Prevention. Global AIDS Program. Atlanta, GA, USA.
Pan American Health Organization. Brasilia, DF, Brazil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Evandro Chagas. Immunology Service. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Evandro Chagas. Immunology Service. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Evandro Chagas. Department of Infectious Diseases. Rio de Janeiro, RJ, Brasil.
National Center for HIV, STD, TB Prevention. Centers for Disease Control and Prevention. Division of STD Prevention. Atlanta, GA, USA.
Pan American Health Organization. Brasilia, DF, Brazil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Evandro Chagas. Immunology Service. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Evandro Chagas. Immunology Service. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Evandro Chagas. Department of Infectious Diseases. Rio de Janeiro, RJ, Brasil.
National Center for HIV, STD, TB Prevention. Centers for Disease Control and Prevention. Division of STD Prevention. Atlanta, GA, USA.
Abstract
The Abbott Determine Rapid Syphilis TP assay is a treponemal test that can be used in resource-poor
settings that lack laboratory facilities. However, this test has not been extensively evaluated. We measured its
sensitivity and specificity by using stored serum specimens (n 567) from all persons who tested Treponema
pallidum hemagglutination assay (TPHA) positive (n 250) or TPHA indeterminate (n 17) in the year 2001
and the first 300 patients in 2001 who tested TPHA negative at the Evandro Chagas Research Institute in Rio
de Janeiro, Brazil. This rapid assay was independently interpreted by three different observers. With TPHA
results as the reference, sensitivity ranged between readers from 95.6 to 98.4% and specificity ranged from 97.3 to 95.7%. There was little interreader variability in the interpretation of results, with approximately 98%
agreement for all reader combinations. Of samples from persons with human immunodeficiency virus (HIV)
infection (n 198), sensitivity was 96.9 to 99.2% and it was 94.4 to 96.3% among HIV-negative persons (n
127). Specificity was 92.4 to 95.5% among HIV-positive persons and 97.2 to 100% among HIV-negative persons. We found this test to have high sensitivity and specificity and little interreader variability, indicating that it may be easily used in resource-poor settings without laboratory facilities. Further studies are needed using this test on whole blood and under the clinical conditions for which it is intended.
Share